Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GI Drugs Cmte. To Weigh Retreatment Study Design For Salix's Xifaxan In Irritable Bowel

This article was originally published in The Pink Sheet Daily

Executive Summary

On Nov. 16, FDA's outside advisors will discuss the design of clinical trials to evaluate the safety, efficacy and durability of response with repeat treatment cycles of rifaximin for diarrhea-predominant IBS.
Advertisement

Related Content

Panel To Help Define Target Population For Xifaxan Reuse In IBS-D
Salix Expects Acquisition Of Oceana, Two Products, To Be Quickly Accretive
FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs
FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs
IBS-D Lead May Go To Tioga With Salix Required To Run Another Trial
IBS-D Lead May Go To Tioga With Salix Required To Run Another Trial
Salix Tumbles With Expected "Complete Response" Letter On Xifaxan In IBS
Xifaxan's Expanded Indication Comes With Additional Safety, Efficacy Trials

Topics

Advertisement
UsernamePublicRestriction

Register

PS072815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel